.png){kind=logo}
Shin Mukai, a pioneering chemical biologist and entrepreneur, brings over 15 years of expertise to the field. With a background in Synthetic Organic/Medicinal Chemistry and a focus on multi-step organic synthesis and computer-aided drug design, Shin has also delved into Biology/Immunology, showcasing skills in conventional and spectral flow cytometry, mass cytometry, single-cell mRNA/ATAC sequencing, and animal experiments.
Having earned Bachelor's and Master's degrees in Chemistry from Kyoto University in Japan, followed by a Ph.D. in Bio-Organic Chemistry from The University of Western Australia, Shin further honed his skills through postdoctoral training at Brigham and Women's Hospital/Harvard Medical School and the Keio University School of Medicine in Japan. Additionally, he pursued entrepreneurship education at Harvard Business School.
In his role as a leader at New Wind Therapeutics L3C, Shin establishes the overarching goals and purpose of the company, articulating its visions and missions globally. He develops strategies to achieve organizational objectives, considering factors such as research and development, market dynamics, and regulatory frameworks. Leading the research team for the preclinical development of novel small-molecule anti-cancer drugs, Shin cultivates an environment of innovation and scientific excellence. He also nurtures the next generation of leading scientists by imparting his unique set of skills to them. Furthermore, Shin ensures clear and efficient communication with diverse stakeholders, including investors, staff, regulatory bodies, and the public.
Encouraging Innovation and Appreciating Success
Most notably, Shin Mukai aims to foster healthy environments where all team members feel empowered to express their opinions without fear. Recognizing that effective communication and transparency are vital for building trust in the workplace, he prioritizes the growth of the company and team members over personal advancement. As a leader, Shin provides unwavering support to team members, ensuring their empowerment and development.
To empower and nurture the team, Shin consistently (i) keeps members informed and involved in decision-making and problem-solving processes, (ii) delegates leadership roles for specific projects or tasks to each team member, (iii) encourages creativity and innovation by granting freedom to explore novel ideas, and (iv) expresses appreciation and acknowledgment for the team's efforts and achievements.
Following the loss of Shin's father to cancer, there emerged a profound passion for combating the disease. In pursuit of this objective, Shin has diligently acquired skills and knowledge essential for cancer research, yielding significant results and contributing to the scientific and medical communities. The research journey commenced with a Master's program at Kyoto University in Japan, focusing on the synthesis of functionalized DNA.
Subsequently, Shin pursued a PhD in Bio-Organic Chemistry at The University of Western Australia, where the focus shifted to the production of novel unnatural amino acids. Post-PhD, the first postdoctoral position at the Keio University School of Medicine in Japan involved the creation of a patented treatment for chronic Graft-Versus-Host Disease alongside the supervision of MD/PhD students. The second postdoctoral role at Brigham and Women's Hospital/Harvard
Medical School (BWH/HMS) demonstrated the clinical significance of macrophage heterogeneity in humans.
Despite extensive experience in scientific and medical research, Shin recognized the importance of gaining pharmaceutical industry experience for the development of novel anti-cancer drugs. Consequently, after completing postdoctoral assignments at BWH/HMS, Shin joined the giant pharmaceutical company Sanofi. Here, he pioneered a new avenue for biology in human B-cells, eosinophils, neutrophils, and mast cells.
Drawing on achievements and expertise from academia and the pharmaceutical industry, Shin co-founded New Wind Therapeutics L3C. The mission is to positively impact the world by developing novel anti-cancer drugs and nurturing the next generation of leading scientists.
Shin Mukai forges a unique path, eschewing the influence of others and determined to blaze a trail in the world. The pivotal decision to delve into cancer research was not swayed by external forces but rooted in a personal experience—the loss of Shin's father to cancer. Recognizing the widespread impact of this disease on individuals and families globally, Shin felt a profound sense of responsibility to contribute to the development of novel cancer therapies
New Wind Therapeutics functions as a Low-profit Limited Liability Company (L3C) with a core focus on social impact. Shin Mukai and his team's dedication to addressing the urgent needs of cancer patients propels every aspect of their work. Operating as an L3C allows them to harmonize scientific advancements with the pursuit of positive social outcomes
Within the realm of New Wind Therapeutics, the commitment to transforming cancer care is deeply rooted in research excellence. Their dynamic research process seamlessly integrates cutting-edge technology, interdisciplinary collaboration, and a profound dedication to targeting Cancer Stem Cells (CSCs).
Acknowledging the existing gap between academia and the pharmaceutical industry, where many innovations from advanced academic research fail to attract industry investment or patent utilization, New Wind Therapeutics L3C emerges as a potential bridge across this divide, often referred to as the Valley of Death.
Being prepared to navigate a landscape of uncertainty and confront challenges associated with market changes and unexpected events is an ongoing and initial challenge for Shin. Effectively managing and mitigating risks is a constant focus
The creation of anti-cancer drugs from scratch involves intricate scientific and technical hurdles. Despite Shin's expertise in organic chemistry/medicinal chemistry and biology/immunology, accessing specialized knowledge and expertise is essential. This requirement prompts collaboration with researchers, clinicians, and other professionals to ensure a comprehensive approach.
As a leader, Shin Mukai actively contributes to the community by enhancing a sense of purpose and connection beyond the workplace. In addition to his roles at New Wind Therapeutics L3C, Shin serves as (i) Council Leader at The U.S.-Japan Council, where he works towards strengthening the relationship between the US and Japan, fostering advancements in scientific and medical research and nurturing the next generation of leaders in both countries. Furthermore, (ii) Acting as a Subject Matter Expert, Shin supports the global community of leaders and innovators across all Harvard Schools.
Shin emphasizes the importance for emerging business leaders and executives to venture beyond their comfort zones, embracing new challenges to foster innovation and growth. Despite the inevitable hurdles and setbacks, resilience, the maintenance of professionalism, and a positive mindset are critical.
According to Shin, qualities such as creativity, genuine enthusiasm, unwavering determination, and courage take precedence over intelligence when it comes to leading and effecting positive change in the world. While leaders are encouraged to be selfless and prioritize the growth of their companies and team members, they must also prioritize their mental and physical health. Shin underscores the significance of avoiding burnout due to excessive stress and encourages leaders not to hesitate to seek support. Effective well-being management not only allows leaders to lead by example in maintaining good health while working efficiently and professionally but also fosters a healthy work environment for their team members
Join our WhatsApp Channel to get the latest news, exclusives and videos on WhatsApp
_____________
Disclaimer: Analytics Insight does not provide financial advice or guidance. Also note that the cryptocurrencies mentioned/listed on the website could potentially be scams, i.e. designed to induce you to invest financial resources that may be lost forever and not be recoverable once investments are made. You are responsible for conducting your own research (DYOR) before making any investments. Read more here.
